Searched for
TAGRISSO
Hospitals warn Central Government Health Scheme reimbursement cap may hurt cancer treatmentA major private hospital group warns of a crisis for advanced cancer patients under the Central Government Health Scheme. A reimbursement c...- AstraZeneca breast cancer medicine slows disease by over six monthsAstraZeneca's new breast cancer pill, Camizestrant, shows promising results. The drug delayed cancer progression by over six months in tria...
- MNC pharma: Time to re-look at them without bias? 8 MNC pharma stocks, 5 with an upside potential of 15 to 52%While they still trade at premium valuations, they have not created much wealth for shareholders in recent times. The age-old theory that h...
- AstraZeneca India recasts biopharma unitAstraZeneca India has laid off over 125 employees in its biopharmaceutical business unit, including senior managers and sales executives. T...
- MNC pharma: Time to relook at them? 8 pharma stocks, 4 with an upside potential of between 16 and 47%In the past four years, several MNC pharma companies announced the sale of a part of their businesses in India. Some of this was part of gl...
- AstraZeneca gets $107 mln Pfizer verdict overturned in US cancer drug patent fightOn Wednesday, U.S. District Judge Matthew Kennelly invalidated Pfizer’s patents related to the cancer drug Nerlynx, overturning a jury's $1...
- Be bullish, just manage risks & desire; 5 midcap stocks for long term investorsIn a bullish market many things change and one of them is the relationship between opportunity and challenges. Given the way markets are pa...
- Indian companies have made a comeback. Will MNCs be able to do it ? 7 MNC pharma stocks with upside potential of up to 21%While they still trade at premium valuations, they have not created wealth for shareholders. The fact is an age-old theory that just having...
- AstraZeneca bets on licencing deals, public-private partnerships for India growthBritish-Swedish drugmaker AstraZeneca is set to launch 15 new products in India from 2023 to 2025, focusing on oncology, cardiovascular, re...
- Will the wave of restructuring help? 7 MNC pharma stocks with upside potential of up to 14%In the last three years, Novartis is the third MNC pharma company which has announced sale of a part of its business in India. Some of thes...
- AstraZeneca targets 2024 growth but mixed views hit sharesIn almost a decade since AstraZeneca fended off a takeover by U.S. rival Pfizer, CEO Pascal Soriot has rebuilt the Anglo-Swedish drugmaker'...
- For calibrating and diversifying risks? 6 midcap stocks from different sectors with the right financial matrixAs the Dalal street continues to be in party mode, staying bullish would appear to be the most logical thing at this point of time. Why fig...
- Miracle pill can keep lung cancer at bay: ReportThe treatment developed by the pharmaceutical group AstraZeneca is called osimertinib and is marketed under the name Tagrisso.
- AstraZeneca starts to make modest profit from Covid-19 vaccineThe Anglo-Swedish company's third-quarter results showed the vaccine contributed one cent to core earnings per share of $1.08, a rise of 14...
- AstraZeneca working on vaccine to prevent and cure Covid: MD Gagandeep SinghAnglo-Swedish pharma company AstraZeneca has mobilised research efforts to advance the development of a novel coronavirus-neutralising long...
- Stocks in the news: HDFC, Ruchi Soya, GIC, Ircon and IRCTCIrcon, Swan Energy, Dish TV India, BF Utilities, Prime Focus, Anant Raj, Andhra Sugars and Sadbhav Engineering will announce their March qu...
- AstraZeneca Pharma India moves Delhi High Court against NPPA demand noticeThe notice of demand alleges that the company has overcharged about Rs 157.38 crore during the period from March 8, 2019 to January 31, 202...
- AstraZeneca says on track to deliver on Covid shots as sales hit $275 mnWhen including production and distribution from partners such as the Serum Institute of India, more than 300 million doses have been suppli...
- Not perfect, but saves lives, AstraZeneca says of COVID-19 vaccineThe two-dose shot, developed with Oxford University, has been hailed as a "vaccine for the world" because it is cheaper and easier to distr...
- AstraZeneca approaches Gilead about potential mergerAstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc. about a potential merger.
Load More
